Preparation of genetically modified donor lymphocytes
| Patient no. . | Transduction efficiency, % . | ΔLNGFR selection efficiency . | Final N of ΔLNGFR+ cells, × 109 . | Yield at the end of production . | |
|---|---|---|---|---|---|
| Yield . | Purity, % . | ||||
| 1 | 15 | NA | 100 | 0.1 | 0.9 |
| 2 | 17 | NA | 96 | 3.285 | 2.7 |
| 3 | 23 | NA | 98 | 0.2 | 1.1 |
| 4 | 23 | NA | 91 | 0.2 | 0.3 |
| 5 | 16 | NA | 95 | 0.465 | 1.7 |
| 6 | 24 | NA | 86 | 0.081 | 0.7 |
| 7 | 25 | NA | 91 | 1.570 | 4.5 |
| 8 | 50 | NA | 96 | 1.870 | 10.8 |
| 9 | 10 | NA | 95 | NA | NA |
| 10 | 20 | NA | 90 | NA | NA |
| 11 | 75 | 0.41 | 97 | 6.5 | NA |
| 12 | 36 | 0.36 | 92 | 3.9 | 1.6 |
| 13 | 49 | 0.77 | 92 | 13.3 | 5.0 |
| 14 | 70 | 0.72 | 95 | 27.0 | 6.5 |
| 15 | 80 | 0.72 | 96 | 12.0 | 8.1 |
| 16 | 52 | 0.69 | 94 | 26.2 | 8 |
| 17 | 35 | 0.8 | 95 | 19.0 | 6.6 |
| 18 | 36 | 0.31 | 93 | 5.3 | 2.6 |
| 19 | 43 | 0.74 | 96 | 19.9 | 6.6 |
| 20 | 45 | 0.57 | 95 | 29.3 | 9.5 |
| 21 | 23 | 0.39 | 94 | 3.8 | 1.2 |
| 22 | 20 | 1.2 | 88 | 7.7 | 10.4 |
| 23 | 32 | 0.57 | 89 | 5.0 | 6 |
| Median | 39.5 | 0.7 | 94 | 12.7 | 7 |
| Range | 10-80 | 0.31-1.2 | 88-100 | 0.081-29.3 | 0.3-10.8 |
| Patient no. . | Transduction efficiency, % . | ΔLNGFR selection efficiency . | Final N of ΔLNGFR+ cells, × 109 . | Yield at the end of production . | |
|---|---|---|---|---|---|
| Yield . | Purity, % . | ||||
| 1 | 15 | NA | 100 | 0.1 | 0.9 |
| 2 | 17 | NA | 96 | 3.285 | 2.7 |
| 3 | 23 | NA | 98 | 0.2 | 1.1 |
| 4 | 23 | NA | 91 | 0.2 | 0.3 |
| 5 | 16 | NA | 95 | 0.465 | 1.7 |
| 6 | 24 | NA | 86 | 0.081 | 0.7 |
| 7 | 25 | NA | 91 | 1.570 | 4.5 |
| 8 | 50 | NA | 96 | 1.870 | 10.8 |
| 9 | 10 | NA | 95 | NA | NA |
| 10 | 20 | NA | 90 | NA | NA |
| 11 | 75 | 0.41 | 97 | 6.5 | NA |
| 12 | 36 | 0.36 | 92 | 3.9 | 1.6 |
| 13 | 49 | 0.77 | 92 | 13.3 | 5.0 |
| 14 | 70 | 0.72 | 95 | 27.0 | 6.5 |
| 15 | 80 | 0.72 | 96 | 12.0 | 8.1 |
| 16 | 52 | 0.69 | 94 | 26.2 | 8 |
| 17 | 35 | 0.8 | 95 | 19.0 | 6.6 |
| 18 | 36 | 0.31 | 93 | 5.3 | 2.6 |
| 19 | 43 | 0.74 | 96 | 19.9 | 6.6 |
| 20 | 45 | 0.57 | 95 | 29.3 | 9.5 |
| 21 | 23 | 0.39 | 94 | 3.8 | 1.2 |
| 22 | 20 | 1.2 | 88 | 7.7 | 10.4 |
| 23 | 32 | 0.57 | 89 | 5.0 | 6 |
| Median | 39.5 | 0.7 | 94 | 12.7 | 7 |
| Range | 10-80 | 0.31-1.2 | 88-100 | 0.081-29.3 | 0.3-10.8 |
Transduction efficiency was measured as the percentage of ΔLNGFR+ cells detected by FACS analysis 4 days after transduction. Yield after ΔLNGFR selection was calculated as the ratio of ΔLNGFR+ cells obtained after immune selection and the number of ΔLNGFR+ cells present after transduction. Purity of immune selection was measured as the percentage of ΔLNGFR+ cells detected by FACS analysis 4 days after selection. Yield at the end of production is calculated as the ratio of ΔLNGFR+ cells present at the end of the manipulation and the number of PBMCs present at the beginning of the overall procedure.
NA indicates data not available.